SLC25A51 and mitochondrial NAD⁺ transport in acute myeloid leukemia: mechanisms, therapeutic potential, and translational perspectives
Human Cell · 19.07.2026 · 39 (8)
DOI: 10.1007/s13577-026-01428-7 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Human Cell, online erschienen am 19.07.2026. Verfasst von Chunmeng Rong und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Ningbo University Yangming Hospital (Yuyao People's Hospital) of Zhejiang Province, Ningbo, Zhejiang, China. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Mitochondria, NAD, Mitochondrial Membrane Transport Proteins. Die Arbeit nennt 37 Literaturangaben. Gefördert von: Natural Science Foundation of Zhejiang Province.
Abstract (Originalsprache)
Acute myeloid leukemia (AML) remains a highly lethal hematologic malignancy characterized by metabolic reprogramming, therapeutic resistance, and poor survival, particularly in older patients. Nicotinamide adenine dinucleotide (NAD⁺) metabolism has emerged as a central driver of AML progression, and recent studies have identified solute carrier family 25 member 51 (SLC25A51) as the primary mitochondrial NAD⁺ transporter in mammalian cells. SLC25A51 regulates mitochondrial redox balance, oxidative phosphorylation, and tricarboxylic acid (TCA) cycle activity, thereby sustaining leukemic proliferation and survival. Structural studies have elucidated its six-transmembrane helix architecture, salt-bridge-mediated transport mechanism, and stabilization by cardiolipin binding. Functional investigations demonstrate that SLC25A51 overexpression correlates with poor prognosis, while its depletion disrupts mitochondrial metabolism, induces apoptosis, and suppresses AML progression in vivo. Therapeutically, pharmacologic inhibition of SLC25A51 with fludarabine, or its combination with hypomethylating agents, such as 5-azacytidine, enhances antileukemic efficacy by perturbing metabolic and epigenetic regulation. Moreover, SLC25A51 expression may serve as a predictive biomarker for mitochondrial-targeted therapies, such as complex I inhibitors. Future translational research should focus on developing selective inhibitors, optimizing combination strategies with demethylating agents and BCL-2 inhibitors, and validating its prognostic significance in clinical cohorts. Collectively, SLC25A51 represents a promising metabolic target with potential to overcome therapeutic resistance and improve patient outcomes in AML. Furthermore, this review discusses its potential implications across distinct genetic subtypes of AML (e.g., mutations in TP53, NPM1, and RAS), thereby highlighting key directions for future translational research.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Ningbo University Yangming Hospital (Yuyao People's Hospital) of Zhejiang Province, Ningbo, Zhejiang, China.
- Key Laboratory of Novel Targets and Drug Study for Neural Repair of Zhejiang Province, School of Medicine, Hangzhou City University, Hangzhou, Zhejiang, China.
- Department of Hematology, Ningbo University Yangming Hospital (Yuyao People's Hospital) of Zhejiang Province, Ningbo, Zhejiang, China. yy_xyzlnk@163.com.
- Key Laboratory of Novel Targets and Drug Study for Neural Repair of Zhejiang Province, School of Medicine, Hangzhou City University, Hangzhou, Zhejiang, China. duansw@hzcu.edu.cn.
Förderung
- Natural Science Foundation of Zhejiang Province
Zitieren
APA
Rong, C., Chen, R., Lou, H., Xia, Y., & Duan, S. (2026). SLC25A51 and mitochondrial NAD⁺ transport in acute myeloid leukemia: mechanisms, therapeutic potential, and translational perspectives. Human Cell, 39(8). https://doi.org/10.1007/s13577-026-01428-7
Vancouver
Rong C, Chen R, Lou H, Xia Y, Duan S. SLC25A51 and mitochondrial NAD⁺ transport in acute myeloid leukemia: mechanisms, therapeutic potential, and translational perspectives. Human Cell. 2026;39(8). doi:10.1007/s13577-026-01428-7
BibTeX
@article{Rong2026,
author = {Rong, Chunmeng and Chen, Ruixiu and Lou, Hanqi and Xia, Yongming and Duan, Shiwei},
title = {SLC25A51 and mitochondrial NAD⁺ transport in acute myeloid leukemia: mechanisms, therapeutic potential, and translational perspectives},
journal = {Human Cell},
year = {2026},
volume = {39},
number = {8},
doi = {10.1007/s13577-026-01428-7}
}
EUVIMED